Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and

Thumbnail Image
Download
Name

E4133.full.pdf

Size

1.24 MB

Format

Adobe PDF

Checksum (MD5)

fc8efe5a674dd2f1f90581c8db4f6b77

Download all files submitted through automated deposit
sword-2018-04-13.original.zip (1.12 MB)
Author(s)
Chahal, Jasdave S.
•
Cooper, Christopher L.
•
McPartlan, Justine S.
•
Tilley, Lucas D.
•
Sidik, Saima M.
•
Lourido, Sebastian
•
Bavari, Sina
•
Ploegh, Hidde L.
•
Khan, Omar Fizal
•
Tsosie, Jonathan
more
Date Issued
July 2016
Journal
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences (U.S.)
Citation
Chahal, Jasdave S. et al. “Dendrimer-RNA Nanoparticles Generate Protective Immunity Against Lethal Ebola, H1N1 Influenza, andToxoplasma Gondiichallenges with a Single Dose.” Proceedings of the National Academy of Sciences 113, 29 (July 2016): E4133–E4142 © 2016 National Academy of Sciences
Version
Final published version
Abstract
Vaccines have had broad medical impact, but existing vaccine technologies and production methods are limited in their ability to respond rapidly to evolving and emerging pathogens, or sudden outbreaks. Here, we develop a rapid-response, fully synthetic, singledose, adjuvant-free dendrimer nanoparticle vaccine platform wherein antigens are encoded by encapsulated mRNA replicons. To our knowledge, this system is the first capable of generating protective immunity against a broad spectrum of lethal pathogen challenges, including H1N1 influenza, Toxoplasma gondii, and Ebola virus. The vaccine can be formed with multiple antigenexpressing replicons, and is capable of eliciting both CD8⁺ T-cell and antibody responses. The ability to generate viable, contaminant-free vaccines within days, to single or multiple antigens, may have broad utility for a range of diseases.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Massachusetts Institute of Technology. Department of Biology
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
http://hdl.handle.net/1721.1/114728
DOI of Published Version
https://doi.org/10.1073/PNAS.1600299113
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.